Poolbeg Pharma PLC (LON:POLB)
6.83p+1.11%
Spriggl Score: Weak— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Patent progress is solid, yet binary trial results in summer 2026 will determine whether this cash-rich biotech survives.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 f…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £47.5M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Poolbeg Pharma PLC and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free